Opinion|Videos|March 26, 2025
Real-World Data and CAR T Selection in Second-Line LBCL: Key Insights From ASH 2024
Author(s)Caron A. Jacobson, MD, MMSc, Peter Riedell, MD
Experts discuss real-world outcomes of lisocabtagene maraleucel (liso-cel) as second-line therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), including data highlights from the CIMBTR registry and insights from a Matching-Adjusted Indirect Comparison (MAIC) of liso-cel vs axicabtagene ciloleucel (axi-cel) in the second-line setting, examining how these findings influence chimeric antigen receptor T-cell therapy (CAR T) selection and decision-making based on patient factors and disease characteristics.
Advertisement
Video content above is prompted by the following:
- At ASH last year, there was an oral presentation looking at real-world outcomes of liso-cel as second-line therapy for R/R LBCL from the CIMBTR registry. What were some data highlights, and how do real-world outcomes influence your day-to-day decision-making?
- What patient factors and/or disease characteristics do you consider when selecting between axi-cel vs liso-cel in the second-line setting? There was updated following from a MAIC of liso-cel vs axi-cel in the second line for R/R LBCL from ASH 2024. Has this data influenced your CAR T selection?
Advertisement
Related to this article
Breast cancer experts address frequently asked questions on adjuvant and metastatic CDK4/6 inhibitor selection in HR-positive breast cancer.
The European Commission approved pembrolizumab plus enfortumab vedotin for muscle-invasive bladder cancer, irrespective of cisplatin eligibility.
Thoracic oncologists weigh how TROP2-directed antibody-drug conjugates fit into sequencing and combination strategies for EGFR-mutated NSCLC.
Patients with pancreatic cancer experience measurable changes in body composition years before diagnosis that differ from those seen in similar individuals without cancer.
Lisaftoclax plus acalabrutinib earned breakthrough therapy status in China for untreated CLL/SLL.
Andrea Cercek, MD, discusses the FDA approval of dostarlimab and its significance for dMMR locally advanced rectal cancer management.
Fadi Haddad, MD, discusses TKI adherence barriers, adverse effect management, and the role of alternative TKI formulations in CML.
Updated ARC-20 data showed casdatifan activity as monotherapy and in combinations across treatment lines in advanced clear cell RCC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval of Dostarlimab Brings Potential Organ-Sparing Approach in dMMR Locally Advanced Rectal Cancer
2
Casdatifan Demonstrates Activity in Advanced Clear Cell RCC
3
Treatment Tailoring and Weighing Alternative Formulations Support Optimal TKI Deployment in CML
4
HER2+ Maintenance Therapy Approvals and Innovative Brain Metastasis Care Reshape Breast Cancer Management
5